Brief: Mereo Biopharma Announces The Presentation Of Updated Data From A Phase 1B/2 Study Of Etigilimab As A Poster At The 2022 American Society Of Clinical Oncology Annual Meeting
27/05/2022 24:53
May 26 (Reuters) - Mereo Biopharma Group PLC MAH0y.F :
* MEREO BIOPHARMA ANNOUNCES THE PRESENTATION OF UPDATED DATA
FROM
A PHASE 1B/2 STUDY OF ETIGILIMAB AS A POSTER AT THE 2022
AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
* MEREO BIOPHARMA GROUP PLC - ETIGILIMAB SAFE AND WELL
TOLERATED,
NO NEW SAFETY SIGNALS
Source text for Eikon: ID:nGNX4r9vRH
Further company coverage: MAH0y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand